Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders: 2010-2025

Historic Net Income towards Common Stockholders for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to -$27.2 million.

  • Northwest Biotherapeutics' Net Income towards Common Stockholders fell 39.35% to -$27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.2 million, marking a year-over-year decrease of 28.46%. This contributed to the annual value of -$85.2 million for FY2024, which is 32.34% down from last year.
  • Northwest Biotherapeutics' Net Income towards Common Stockholders amounted to -$27.2 million in Q3 2025, which was down 70.55% from -$15.9 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Net Income towards Common Stockholders peaked at $213.9 million during Q4 2021, and registered a low of -$32.9 million during Q3 2022.
  • For the 3-year period, Northwest Biotherapeutics' Net Income towards Common Stockholders averaged around -$19.3 million, with its median value being -$18.9 million (2024).
  • Examining YoY changes over the last 5 years, Northwest Biotherapeutics' Net Income towards Common Stockholders showed a top increase of 176.31% in 2021 and a maximum decrease of 257.01% in 2021.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Net Income towards Common Stockholders stood at $213.9 million in 2021, then slumped by 113.23% to -$28.3 million in 2022, then spiked by 49.40% to -$14.3 million in 2023, then plummeted by 99.02% to -$28.5 million in 2024, then plummeted by 39.35% to -$27.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$27.2 million in Q3 2025, compared to -$15.9 million in Q2 2025 and -$19.6 million in Q1 2025.